Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.
Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. · 2010
Read Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. by Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2922327.txt.
Introduction
Patil and co-authors dissected in 2010 how weak chemical forces at a drug's binding site decide whether a lead compound becomes a medicine. Using computer docking, they placed a family of small molecules into two related cancer kinases, c-Src and c-Abl, and scored the fit. The forces of interest are hydrophobic contacts, where greasy surfaces huddle away from water, and hydrogen bonds, the directional attractions between polar atoms.
Three docking engines plus interaction-mapping software let them compare pose by pose. Statistical models built from the docked structures showed that tuning greasy contact area together with a few well-placed hydrogen bonds predicted binding strength and selectivity between the two kinases. The authors distill design rules: fill the hydrophobic pocket snugly first, then anchor with bonds that the wrong target cannot match.
Catalog record
| CREATOR | Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing By Rohan Patil, Suranjana Das, Ashley Stanley, Lumbani Yadav, Akulapalli Sudhakar, Ashok K. Varma, Sridhar Hannenhalli Published in: PLoS ONE DOI: 10.1371/journal.pone.0012029 ABSTRACT Background Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are key players in stabilizing energetically-favored ligands, in an open conformational environment of protein structures. However, it is still poorly understood how the binding parameters associated with these interactions facilitate a drug-lead to recognize a specific target and improve drugs efficacy. To understand this, comprehensive analysis of hydrophobic interactions, hydrogen bonding and binding affinity have been analyzed at the interface of c-Src and c-Abl kinases and 4-amino substituted 1H-pyrazolo [3, 4-d] pyrimidine compounds. Methodology In-silico docking studies were performed, using Discovery Studio software modules LigandFit, CDOCKER and ZDOCK, to investigate the role of ligand binding affinity at the hydrophobic pocket of c-Src and c-Abl kinase. Hydrophobic and hydrogen bonding interactions of docked molecules were compared using LigPlot program. Furthermore, 3D-QSAR and MFA calculations were scrutinized to quantify the role of weak interactions in binding affinity and drug efficacy. Conclusions The in-silico method has enabled us to reveal that a multi-targeted small molecule binds with low affinity to its respective targets. But its binding affinity can be altered by integrating the conformationally favored functional groups at the active site of the ligand-target interface. Docking studies of 4-amino-substituted molecules at the bioactive cascade of the c-Src and c-Abl have concluded that 3D structural folding at the protein-ligand groove is also a hallmark for molecular recognition of multi-targeted compounds and for predicting their biological activity. The results presented here demonstrate that hydrogen bonding and optimized hydrophobic interactions both stabilize the ligands at the target site, and help alter binding affinity and drug efficacy. INTRODUCTION Advances in the field of structural biology have provided tremendous opportunities for computational biologists to design small-molecule drug leads with better biological activity and minimal side effects for a disease-specific target. Modern bioinformatics tools could reduce the time needed to prioritize lead compounds. Scientists have been paying more attention to in-silico approaches since the first peptide-based HIV protease inhibitors were developed [1], followed by a target for antihypertension [2], inhibitors of the influenza virus [3] and H5N1 avian influenza [4]–[5], using a structure-based drug design [6]–[10]. Even with such advances, designing a novel anti-cancer drug that works effectively on a patient is still out of reach. Considering the role of protein structures in predicting protein function, we assume that the complexity of each disease can be unraveled if the structure of disease-associated molecules can be accurately visualized in three dimensions at the atomic level. The protein structure provides information about the precise position of each atom and the molecules present in crystallographic forms. This helps in elaborating the location of an active site at the molecular surface of the protein structure where active ligands can be placed. Weak intermolecular interactions play an important role in stabilizing a ligand energetically at the interface of a protein structure. In this study, we have explored the effect of weak intermolecular interactions on the binding affinity between ligand-protein complexes in order to improve drug efficacy [11]–[13]. Studies of strong covalent bonds, weak hydrophobic interactions and hydrogen bonds raise more questions than have been previously answered [14]. If energetically stabilized drug-like compounds are trapped at the bioactive core of the target site, holding all the biochemical and conformational features, then how is the side effect manifested? How is the binding affinity between drug-ligand complexes associated with drug efficacy? If a suitable environment is provided, are hydrophobic interactions and hydrogen bonds interchangeable? Furthermore, computational biologists (in-silico) are challenged to find supporting factors that bring long-range associated ligand-target complex molecules into small regions where biological activity can be altered. To resolve all these issues, a multi-model approach is needed that explores the dynamic nature of weak intermolecular interactions at the target-drug interface. An increased number of protein structures in the Protein Data Bank have also provided novel opportunities for scientists and clinicians to visualize disease-associated molecules in three dimensions. A drug lead can be designed at the active core of the protein-ligand interface, where the binding affinity is dominated by a small number of atoms [15]–[17]. The predicted hierarchical pathways depicted in Fig. 1 show in-silico optimization of the role of weak intermolecular interactions between the ligand-target binding affinity and biological activity. This information will encourage scientists to study the interrelationship between hydrophobic interactions and hydrogen bonding when developing new drugs. Most ligands exhibits low binding affinity and thus, they can select the number of targets associated with hydrogen bonds [18] ( Fig. 1A ), however, tight binding is observed if hydrophobic interactions are optimized at the expense of hydrogen bonds [19] ( Fig. 1B ) This schematic representation reveals that low-affinity binders, such as 4-amino substituted pyrimidine derivatives, can be selected and screened for biological activity in a multi-targeted structural environment. Furthermore, incorporation of functional group or metal atoms at the ligand site or target site can increase specificity and binding affinity for one of the target ( Figs 1C i, ii, iii ) even as, major unanswered questions may still need re-evaluation. Does this modified target-drug interface; (1) improve binding affinity, (2) help in finding a specific target, and (3) improve drug efficacy for drug design? To find the answers to these questions focused studies are required to evaluate the role of weak intermolecular interactions in drug discovery. However, finding a suitable target for drug design and development, using structure-based activity relationships, is not a biased approach. Currently, computational biologists face the challenges of designing small molecule inhibitors using experimentally determined structures and improving the biological activity of drug-leads. [Figure: Conformational association of an energetically favored ligand and specific target.The ligand is associated to the specific target with hydrogen bonds and hydrophobic interactions inferring the biological activity of compounds. (A) The hypothetical model where the ligand is forming hydrogen bonds to target. (B) The ligand is associated with hydrophobic interactions. (Ci) target is modified. (Cii) ligand is modified. (Ciii) ligand is allied with metal-associated hydrogen bonds for a specific target showing the interrelation between long-range hydrogen bonds and hydrophobic interactions.] To initiate a new approach for drug- design and development, the atomically resolved structure at the ligand-protein interface (i. e, a hot point) is needed [20], In this approach, the positions of a few atoms are stabilized by the number of biophysical parameters such as size, shape, molecular weight, hydrogen bonds, hydrophobic interactions, van der Waals forces and salt bridges [21]–[22]. Hence, any small molecule that binds to a target loses its internal freedom, translational and rotational entropy [23]. After analyzing the interactions that are important for stabilizing the protein-ligand complexes, the focus shifts to the surrounding regions of the hot spot (i.e., the hot regions). Here, the hydrophobic –pocket- associated hot spot and hot regions between 4-amino substituted small molecules and the c-Src [24] and c-Abl [25] protein kinase, have been focused. It is well known that kinases are structurally flexible, thus the dynamic nature of the weak intermolecular interactions of 4-amino-substituted dock molecules at the target-ligand interface can be elaborated. Kinases are well